<DOC>
	<DOCNO>NCT02107963</DOCNO>
	<brief_summary>Background GD2 well-characterized tumor antigen neuroblastoma , also express osteosarcomas sarcoma . T cell express 1st generation anti-GD2 chimeric antigen receptor ( CARs ) safe mediate modest antitumor activity patient refractory neuroblastoma . A 3rd generation anti-GD2-CAR ( GD2-CAR.OX40.28.z.ICD9 ) produce hold promise increase activity compare 1st generation GD2-CAR already study clinical trial . As added safety measure , vector include suicide switch comprise caspase dimerization domain ( ICD9 ) activate small molecule induce death genetically engineer cell induce untoward toxicity . Objectives Primary : Determine feasibility produce anti GD2-CAR cell meeting establish release criterion assess safety administer escalate dos anti-GD2-CAR engineer T cell child young adult GD2+ solid tumor , include neuroblastoma , follow cyclophosphamide-based lymphodepletion . Secondary : 1 . Determine administration anti-GD2-CAR engineer T cell mediate antitumor effect child young adult GD2+ solid tumor ; 2 . Measure persistence adoptively transfer anti-GD2-CAR T cell correlate antitumor effect ; 3 . Extend information regard prevalence intensity GD2 expression non-neuroblastoma , non-osteosarcoma solid tumor child young adult ; 4 . If unacceptable toxicity occur possibly , probably likely relate anti-GD2-CAR T cell , assess capacity AP1903 , dimerizing agent , mediate clearance genetically engineer cell resolve toxicity ; 5 . Assess toxicity AP1903 administer mediate clearance anti-GD2-CAR T cell . Eligibility Patients 1-35 year age , least 15 kg , osteosarcoma GD2+ solid tumor ( include neuroblastoma ) recur responded standard therapy deem incurable standard therapy . Design After apheresis collect T cell transduction , patient receive cyclophosphamide 1800mg/m ( 2 ) /d lymphodepleting regimen . A phase I cell dose escalation scheme use 4 dose level ( 1 x 10 ( 5 ) transduce T cells/kg ; 1 x 10 ( 6 ) transduce T cells/kg ; 3 x 10 ( 6 ) transduce T cells/kg ; 1 x 10 ( 7 ) transduce T cells/kg ) , use standard 3 plus 3 dose escalation design . An expand group total 12 patient treated high dose , comprise least 6 osteosarcoma patient . Patients monitor toxicity , antitumor effect persistence anti-GD2-CAR T cell . Patients PR , SD may receive 2nd cycle next high dose level minimum 60 day follow completion first cycle eligibility criterion meet . A maximum 36 patient may treat study . Given likelihood patient non-osteosarcoma meet criterion GD2 expression eligible enrollment , 72 subject screen enroll maximum 36 patient treatment . Up 2-3 patient accrue per month , therefore study may require 2-3 year complete enrollment treatment .</brief_summary>
	<brief_title>A Phase I Trial T Cells Expressing Anti-GD2 Chimeric Antigen Receptor Children Young Adults With GD2+ Solid Tumors</brief_title>
	<detailed_description>Background GD2 well-characterized tumor antigen neuroblastoma , also express osteosarcomas sarcoma . T cell express 1st generation anti-GD2 chimeric antigen receptor ( CARs ) safe mediate modest antitumor activity patient refractory neuroblastoma . A 3rd generation anti-GD2-CAR ( GD2-CAR.OX40.28.z.ICD9 ) produce hold promise increase activity compare 1st generation GD2-CAR already study clinical trial . As added safety measure , vector include suicide switch comprise caspase dimerization domain ( ICD9 ) activate small molecule induce death genetically engineer cell induce untoward toxicity . Objectives Primary : Determine feasibility produce anti GD2-CAR cell meeting establish release criterion assess safety administer escalate dos anti-GD2-CAR engineer T cell child young adult GD2+ solid tumor , include neuroblastoma , follow cyclophosphamide-based lymphodepletion . Secondary : 1 . Determine administration anti-GD2-CAR engineer T cell mediate antitumor effect child young adult GD2+ solid tumor ; 2 . Measure persistence adoptively transfer anti-GD2-CAR T cell correlate antitumor effect ; 3 . Extend information regard prevalence intensity GD2 expression non-neuroblastoma , non-osteosarcoma solid tumor child young adult ; 4 . If unacceptable toxicity occur possibly , probably likely relate anti-GD2-CAR T cell , assess capacity AP1903 , dimerizing agent , mediate clearance genetically engineer cell resolve toxicity ; 5 . Assess toxicity AP1903 administer mediate clearance anti-GD2-CAR T cell . Eligibility Patients 1-35 year age , least 15 kg , osteosarcoma GD2+ solid tumor ( include neuroblastoma ) recur responded standard therapy deem incurable standard therapy . Design After apheresis collect T cell transduction , patient receive cyclophosphamide 1800mg/m ( 2 ) /d lymphodepleting regimen . A phase I cell dose escalation scheme use 4 dose level ( 1 x 10 ( 5 ) transduce T cells/kg ; 1 x 10 ( 6 ) transduce T cells/kg ; 3 x 10 ( 6 ) transduce T cells/kg ; 1 x 10 ( 7 ) transduce T cells/kg ) , use standard 3 plus 3 dose escalation design . An expand group total 12 patient treated high dose , comprise least 6 osteosarcoma patient . Patients monitor toxicity , antitumor effect persistence anti-GD2-CAR T cell . Patients PR , SD may receive 2nd cycle next high dose level minimum 60 day follow completion first cycle eligibility criterion meet . A maximum 36 patient may treat study . Given likelihood patient non-osteosarcoma meet criterion GD2 expression eligible enrollment , 72 subject screen enroll maximum 36 patient treatment . Up 2-3 patient accrue per month , therefore study may require 2-3 year complete enrollment treatment . Treatment Schema : Upon enrollment : Apheresis volume estimate base upon patient weight target cell dose . PBMC may cryopreserved necessary prior initiation CAR transduction . CAR transduce T cell may cryopreserved necessary prior administration . At least 7 28 day may elapse apheresis initiation chemotherapy . Day 3 , 2 : Cyclophosphamide , 1800 mg/m2 per day IV 2 hour daily x2 , Mesna , 1800 mg/m2 per day continuous IV infusion daily x2 Day 0 : 30-60 minute prior cell infusion administer diphenhydramine 1 mg/kg/d ( max 50 mg ) IV po , acetaminophen 15 mg/kg/dose ( max 650 mg ) po Infuse anti-GD2-CAR T cell 15-30 minute</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Diagnosis ( ) Osteosarcoma , neuroblastoma melanoma treated standard frontline therapy judge incurable standard therapy , base upon fact unresectable , metastatic , progressive/persistent recurrent . Evaluable disease must present . ) For histology except osteosarcoma neuroblastoma , pathologic review frozen tissue must document GD2+ expression . Positive expression define least 2+ expression ( 04+ scale ) &gt; 50 percent tumor cell use antiGD2 mAb 14G2a . If adequate archive frozen tissue available , may utilize , , patient may undergo biopsy follow enrollment obtain tissue ass GD2 expression , follow restriction . ii ) Patients histology osteosarcoma neuroblastoma must adequate accessible tumor biopsy ( least 1 cm diameter ) . iii ) Procedures employed acquire biopsy tumor lysates limit percutaneous needle core biopsy , thoracoscopic excision open biopsy readily accessible lesion . Pulmonary lesion may biopsied extensive surgery thoracotomy laparotomy employ . iv ) Patients require biopsy enrolled opinion principal investigator , tumor site place patient substantial risk biopsy procedure . 2 . Weight great equal 15 kg 3 . Age less equal 35 year old time enrollment . 4 . Prior Therapy : 1 . The patient malignancy must relapse failed respond frontline curative therapy and/or must curative treatment option available time study entry . 2 . There limit number prior treatment regimen . However , patient must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior study enrollment . Any grade 3 4 nonhematologic toxicity previous therapy must resolve grade 2 less . 3 . Myelosuppressive chemotherapy : Patients must receive myelosuppressive chemotherapy within 3 week enrollment ( 6 week prior nitrosourea ) . 4 . Hematopoietic growth factor : At least 7 day must elapse since completion therapy growth factor . At least 14 day must elapse receive pegfilgrastim . 5 . At least 7 day must elapse since completion therapy biologic agent , target agent , tyrosine kinease inhibitor metronomic nonmyelosuppressive regimen . 6 . Monoclonal antibody : At least 4 week must elapse since prior therapy include monoclonal antibody . 7 . Radiotherapy : 3 week must elapse since XRT 5 . Performance status : ECOG 0 , 1 2 , child less equal 10 year age , Lansky great equal 60 . 6 . Cardiac function : Left ventricular ejection fraction great equal 40 percent fractional shortening great equal 28 percent . 7 . Liver function : Serum total bilirubin &lt; 2 mg/dl , serum AST ALT less equal 3 x upper limit normal . Patients Gilbert syndrome exclude requirement normal bilirubin patient exclude liver enzyme elevation due tumor involvement . ( Gilbert syndrome find 310 % general population , characterize mild , chronic unconjugated hyperbilirubinemia absence liver disease overt hemolysis ) . NOTE : Adult value use calculate hepatic toxicity determine eligibility , standard POB phase I trials . 8 . Renal function : Ageadjusted normal serum creatinine accord follow table creatinine clearance great equal 60 ml/min/1.73 ( 2 ) . Age less equal 5 Maximum serum creatinine ( mg/dl ) 0.8 Age great 5 less equal 10 Maximum serum creatinine ( mg/dl ) 1.0 Age great 10 less equal 15 Maximum serum creatinine ( mg/dl ) 1.2 Age great 15 Maximum serum creatinine ( mg/dl ) 1.5 9 . Marrow function : ANC must &gt; 750/mm ( 3 ) , platelet count must great equal 75,000/mm ( 3 ) ( achieve transfusion ) . 10 . Ability give inform consent . For patient &lt; 18 year age , legal guardian must give informed consent . Pediatric patient include ageappropriate discussion order obtain verbal assent . 11 . Durable power attorney form offer ( patient ( Bullet ) 18 year age ) . 12 . Birth Control Female male patient ( relevant partner ) must willing practice birth control ( include abstinence ) two month treatment , childbearing potential . EXCLUSION CRITERIA : 1 . Concurrent Illnesses Clinically significant systemic illness ( e.g . serious active infection significant cardiac , pulmonary , hepatic organ dysfunction ) , judgment PI would compromise patient ability tolerate protocol therapy significantly increase risk complication . Peripheral nerve symptom prior therapy tumor compression &gt; grade 1 . 2 . Untreated CNS metastasis Extradural mass invade brain parenchyma parameningeal tumor without evidence leptomeningeal spread render patient ineligible . Patients previous CNS tumor involvement treat stable least 6 week follow completion therapy eligible . 3 . Prior Therapy Previous treatment genetically engineer GD2CAR T cell . Previous vaccine therapy , antiGD2 mAb therapy therapy genetically engineer T cell exclusion criterion . 4 . Lactating pregnant female ( due risk fetus newborn ) . 5 . Active HIV , HBV HCV infection . 6 . Immune Therapies Patients require systemic corticosteroid immunosuppressive therapy . Immunosuppressive therapy must stop least 14 day prior cell infusion . INCLUSION OF WOMEN AND MINORITIES : Both men woman race ethnic group eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 31, 2017</verification_date>
	<keyword>GD2-Expressing Tumors</keyword>
	<keyword>Anti-GD2 Chimeric Antigen Receptor</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Adoptive Immunotherapy</keyword>
	<keyword>Sarcomas</keyword>
</DOC>